Initial Management of Withdrawal and Pain in Hospitalized Patients with Opioid Use Disorder (OUD) Using Fentanyl

- Patients using <u>></u>3 bags of fentanyl daily: use this approach with these doses, even if patient received higher doses during a recent hospitalization.
- Patients using <2 bags fentanyl or who have critical illness, older age, frailty, or significant renal/hepatic impairment: reduce doses by 50%.

1. Assess & Diagnose OUD

Please reach out for expert guidance:

PPMC: Addiction Consult Team, Psych CL HUP: Psych CL, MEND, Pain Pharmacy HUP HUP OB: Penn Family Medicine PAH: Psych CL

- Diagnose OUD using DSM-5 criteria & document current substance use: drugs, quantity, route, & amount
- Ask patient about goals and history of treatment: medications, psychosocial, residential, or other
- Obtain urine drug test when feasible; do not wait for results to initiate treatment

2. Stabilize & Engage

Many patients have overlapping withdrawal and pain. Partner with patients to develop a supportive regimen that aligns patient goals for comfort with our responsibility to provide a safe environment.

Continue outpatient OUD treatment: if stable on methadone/buprenorphine, confirm dose (PDMP for buprenorphine, call opioid treatment program for methadone) and continue home dose if no interruptions have occurred in treatment

Start a long-acting opioid (methadone or buprenorphine preferred) while hospitalized

Patient <u>interested in</u> methadone on discharge \rightarrow Start methadone, then increase daily to 60mg/day if no discharge barriers Patient <u>interested in</u> buprenorphine on discharge \rightarrow Start buprenorphine, use traditional or low-dose initiation Patient <u>undecided about</u> methadone/buprenorphine on discharge \rightarrow Use methadone (or oxycodone ER) while deciding Patient declines methadone/buprenorphine on discharge \rightarrow Use methadone (or oxycodone ER) while hospitalized

- Methadone: 30mg AM + 10mg PM daily PO, can order without Psych consult. If patient declines or is undecided about methadone on discharge, use shared decision-making to either continue 30+10mg daily or increase daily to 60mg/day (per "New methadone maintenance" below). If refractory vomiting, use IV with 50% dose reduction.
- Buprenorphine: traditional induction as monotherapy for withdrawal or low-dose induction with overlapping opioids
- Oxycodone ER (limited evidence): if methadone & buprenorphine contra-indicated, use oxycodone ER 40-60mg q8h

Treat withdrawal

- (1) Use non-opioid adjuvants for opioid and possible xylazine withdrawal: consider scheduled clonidine & other medications PRN or scheduled per *Opioid Withdrawal Order-Set* and *Xylazine Withdrawal Guidelines*.
- (2) Consider oral short-acting opioids for withdrawal as a supplement to long-acting opioids
 - <u>Set expectations</u>: goal is to treat withdrawal/pain without excess sedation; administered medications may not achieve the same effect as drug use; short-acting opioids will not be continued for withdrawal on discharge.
 - <u>Dosing</u>: oxycodone IR 20mg (or hydromorphone 8mg) q4h scheduled, hold for sedation. Can increase oxycodone IR by 10mg (4mg for hydromorphone) q4h during the first 24 hours until COWS <6.
 - <u>Timing</u>: goal is to cross-taper short-acting opioids with a long-acting opioid (methadone/buprenorphine preferred) within ~72h. Longer periods might be necessary for acute pain or craving, based on expert guidance.

Treat acute pain

- (1) Use non-opioids: scheduled acetaminophen, NSAIDs (ketorolac or ibuprofen), topicals, and ice/heat. Consider ketamine see formulary for PO (on general units at HUP only) or IV (in ICU), requires specialist approval
- (2) Consider opioids for analgesia: patients with OUD have high tolerance and require higher opioid doses for analgesia.
 - Oral short-acting opioids: Use doses per opioid withdrawal dosing guidance above.
 - <u>IV opioids and PCAs</u>: Use IV formulations and/or PCA for the same indications as you would in patients without OUD (eg. post-op, NPO). Typical PCA starting dose for patients using fentanyl: hydromorphone 2mg load; 0.5mg basal, 0.5mg demand q15 min, no lockout. Can escalate demand by 0.5mg up to 2mg. Beyond this, seek expert guidance.
 Offer to enlit method and (hyperparabine into 2, 4), daily deeps for increased analysis offert.
 - <u>Offer to split methadone/buprenorphine</u> into 3-4x daily doses for increased analgesic effect.

3. Transition to Maintenance OUD Treatment & Plan for Discharge

Encourage all patients to transition to methadone/buprenorphine. Counsel about benefits, risks, and requirements (eg., daily visits to OTP for methadone). Consider clinical trajectory and discharge planning (eg., see below for DC to SNF).

- New methadone maintenance: See *Methadone Induction Pathway*. Increase AM methadone by 10mg/day up to 60mg total daily dose while reducing short-acting opioids by ~10-25%/day. Seek expert guidance beyond 60mg/day.
- New buprenorphine maintenance: See Buprenorphine Induction Pathway. Can use traditional or low-dose induction.
- **Declined methadone/buprenorphine**: Either (1) abruptly stop opioids on discharge (preferred because tapering reduces tolerance and increases risk of post-hospitalization overdose) or (2) taper opioids by 25% every 1-3 days.
- Narcan: On admission, order take-home Narcan nasal spray and have MyPennPharmacy deliver to patient
- **DC to home or community**: Set up linkage to OUD care (bridge prescription & appointment for buprenorphine; nextday OTP intake for methadone). In general, short-acting opioids should not be prescribed on discharge.
- DC to SNF/rehab: New methadone starts may not be compatible with discharge to SNF. Ask for expert guidance.